Cargando…

IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies

Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Audsley, Katherine M., Wagner, Teagan, Ta, Clara, Newnes, Hannah V., Buzzai, Anthony C., Barnes, Samantha A., Wylie, Ben, Armitage, Jesse, Kaisho, Tsuneyasu, Bosco, Anthony, McDonnell, Alison, Cruickshank, Mark, Fear, Vanessa S., Foley, Bree, Waithman, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450325/
https://www.ncbi.nlm.nih.gov/pubmed/34552594
http://dx.doi.org/10.3389/fimmu.2021.735133
_version_ 1784569617172135936
author Audsley, Katherine M.
Wagner, Teagan
Ta, Clara
Newnes, Hannah V.
Buzzai, Anthony C.
Barnes, Samantha A.
Wylie, Ben
Armitage, Jesse
Kaisho, Tsuneyasu
Bosco, Anthony
McDonnell, Alison
Cruickshank, Mark
Fear, Vanessa S.
Foley, Bree
Waithman, Jason
author_facet Audsley, Katherine M.
Wagner, Teagan
Ta, Clara
Newnes, Hannah V.
Buzzai, Anthony C.
Barnes, Samantha A.
Wylie, Ben
Armitage, Jesse
Kaisho, Tsuneyasu
Bosco, Anthony
McDonnell, Alison
Cruickshank, Mark
Fear, Vanessa S.
Foley, Bree
Waithman, Jason
author_sort Audsley, Katherine M.
collection PubMed
description Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model. We show that vaccination in combination with IFNβ induces significantly greater expansion of tumor-specific CD8(+) T cells than the other type I IFN subtypes tested. Optimal expansion was dependent on the presence of XCR1(+) dendritic cells, CD4(+) T cells, and CD40/CD40L signaling. Therapeutically, vaccination with IFNβ delayed tumor progression when compared to vaccination without IFN. When vaccinated in combination with anti-PD-L1 checkpoint blockade therapy (CPB), the inclusion of IFNβ associated with more mice experiencing complete regression and a trend in increased overall survival. This work demonstrates the potent adjuvant activity of IFNβ, highlighting its potential to enhance cancer vaccination strategies alone and in combination with CPB.
format Online
Article
Text
id pubmed-8450325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84503252021-09-21 IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies Audsley, Katherine M. Wagner, Teagan Ta, Clara Newnes, Hannah V. Buzzai, Anthony C. Barnes, Samantha A. Wylie, Ben Armitage, Jesse Kaisho, Tsuneyasu Bosco, Anthony McDonnell, Alison Cruickshank, Mark Fear, Vanessa S. Foley, Bree Waithman, Jason Front Immunol Immunology Cancer vaccination drives the generation of anti-tumor T cell immunity and can be enhanced by the inclusion of effective immune adjuvants such as type I interferons (IFNs). Whilst type I IFNs have been shown to promote cross-priming of T cells, the role of individual subtypes remains unclear. Here we systematically compared the capacity of distinct type I IFN subtypes to enhance T cell responses to a whole-cell vaccination strategy in a pre-clinical murine model. We show that vaccination in combination with IFNβ induces significantly greater expansion of tumor-specific CD8(+) T cells than the other type I IFN subtypes tested. Optimal expansion was dependent on the presence of XCR1(+) dendritic cells, CD4(+) T cells, and CD40/CD40L signaling. Therapeutically, vaccination with IFNβ delayed tumor progression when compared to vaccination without IFN. When vaccinated in combination with anti-PD-L1 checkpoint blockade therapy (CPB), the inclusion of IFNβ associated with more mice experiencing complete regression and a trend in increased overall survival. This work demonstrates the potent adjuvant activity of IFNβ, highlighting its potential to enhance cancer vaccination strategies alone and in combination with CPB. Frontiers Media S.A. 2021-09-06 /pmc/articles/PMC8450325/ /pubmed/34552594 http://dx.doi.org/10.3389/fimmu.2021.735133 Text en Copyright © 2021 Audsley, Wagner, Ta, Newnes, Buzzai, Barnes, Wylie, Armitage, Kaisho, Bosco, McDonnell, Cruickshank, Fear, Foley and Waithman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Audsley, Katherine M.
Wagner, Teagan
Ta, Clara
Newnes, Hannah V.
Buzzai, Anthony C.
Barnes, Samantha A.
Wylie, Ben
Armitage, Jesse
Kaisho, Tsuneyasu
Bosco, Anthony
McDonnell, Alison
Cruickshank, Mark
Fear, Vanessa S.
Foley, Bree
Waithman, Jason
IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title_full IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title_fullStr IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title_full_unstemmed IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title_short IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
title_sort ifnβ is a potent adjuvant for cancer vaccination strategies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450325/
https://www.ncbi.nlm.nih.gov/pubmed/34552594
http://dx.doi.org/10.3389/fimmu.2021.735133
work_keys_str_mv AT audsleykatherinem ifnbisapotentadjuvantforcancervaccinationstrategies
AT wagnerteagan ifnbisapotentadjuvantforcancervaccinationstrategies
AT taclara ifnbisapotentadjuvantforcancervaccinationstrategies
AT newneshannahv ifnbisapotentadjuvantforcancervaccinationstrategies
AT buzzaianthonyc ifnbisapotentadjuvantforcancervaccinationstrategies
AT barnessamanthaa ifnbisapotentadjuvantforcancervaccinationstrategies
AT wylieben ifnbisapotentadjuvantforcancervaccinationstrategies
AT armitagejesse ifnbisapotentadjuvantforcancervaccinationstrategies
AT kaishotsuneyasu ifnbisapotentadjuvantforcancervaccinationstrategies
AT boscoanthony ifnbisapotentadjuvantforcancervaccinationstrategies
AT mcdonnellalison ifnbisapotentadjuvantforcancervaccinationstrategies
AT cruickshankmark ifnbisapotentadjuvantforcancervaccinationstrategies
AT fearvanessas ifnbisapotentadjuvantforcancervaccinationstrategies
AT foleybree ifnbisapotentadjuvantforcancervaccinationstrategies
AT waithmanjason ifnbisapotentadjuvantforcancervaccinationstrategies